Methods and compositions for treating cancer
AssigneeThe University of Chicago
InventorsLev Becker, Chang Cui
Life of this patent
Estimating the term…
Abstract
Embodiments are directed to: (i) neutrophil secreted factors that have the capacity to kill a broad range of cancer cells without affecting the viability of non-cancer cells. Two neutrophil killing factors have been identified by the inventors: (1) eosinophil cationic protein (ECP) and (2) neutrophil elastase (ELANE); or (ii) therapeutic compositions that include CD95 degrading polypeptide components and methods of treating cancer with the same.
Claims7
A method for killing a cancer cell by CD95 degradation comprising administering to a patient that has cancer an effective amount of a serine protease that cleaves CD95, wherein the cancer expresses CD95, and wherein the serine protease comprises:
- a pancreatic porcine elastase (pELA1) polypeptide that is 96% to 100% identical to SEQ ID NO:
- 6;
- or
- a pELA1 polypeptide having 225 to 250 contiguous acids of pELA1 that is 98% to 100% identical to SEQ ID NO:6 (pELA1).
Dependencies are inferred from the claim text.